Last updated: February 12, 2026
What Is NDC 60505-0258?
Drug code 60505-0258 corresponds to Venclexta (venetoclax), a BCL-2 inhibitor used primarily in the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
Market Overview
Market Size and Growth
- The global hematologic malignancies treatment market was valued at approximately $15.2 billion in 2022.
- The BCL-2 inhibitor segment, anchored by venetoclax, accounts for roughly 60% of this market, driven by its approvals for CLL and AML.
- CAGR (Compound Annual Growth Rate) forecasted at 7.5% through 2027 (source [1]).
Competitive Landscape
- Key competitors include AbbVie's Imbruvica (ibrutinib), Gilead's用Vịlimis (venetoclax + obinutuzumab), and generic formulations.
- The approvals of combination therapies—particularly venetoclax with obinutuzumab—accelerate market penetration.
Regulatory Approvals
- FDA approval for CLL with or without 17p deletion (April 2016).
- Expanded approval for AML in combination with azacitidine, decitabine, or low-dose cytarabine (September 2021).
Pricing Benchmarks
- The list price of Venclexta is approximately $13,000 per month, translating to $156,000 annually (source [2]).
Price Projection Analysis
Pricing Factors
- Patent exclusivity maintains high pricing levels through at least 2030.
- Biosimilars or generics are not expected before 2030, barring patent challenges.
- Pricing for combination regimens tends to be higher, reflecting enhanced efficacy and convenience.
Market Dynamics Impacting Price
- Volume growth driven by expanded indications and combination therapies.
- Payer negotiations and cost-containment strategies may pressure list prices.
- The emergence of biosimilars could create downward pricing pressure post-2030.
Projected Pricing Trends (2023–2030)
| Year |
Estimated Average Price (per month) |
Reasoning |
| 2023 |
$13,000 |
Current list price maintained; no new biosimilars in market. |
| 2024 |
$13,000 |
Stable pricing, with minor discounts negotiated. |
| 2025 |
$12,950 |
Slight downward pressure via discounting strategies. |
| 2026 |
$12,900 |
Continued adjustments; increased competition unlikely. |
| 2027 |
$12,850 |
Price stabilization persists amid high demand. |
| 2028 |
$12,850 |
No significant price reduction expected. |
| 2029 |
$12,800 |
Slight decline anticipated with patent expiry looming. |
| 2030 |
$12,700 |
Biosimilars expected entering market, pressuring prices. |
Note: The projections assume current patent protections and no major regulatory changes. Price declines will accelerate once biosimilars or generics receive approval and market entry.
Revenue Projections (2023–2030)
| Year |
Estimated Units Sold |
Approximate Revenue (in billions) |
Notes |
| 2023 |
0.8 million |
$13 billion |
Based on current pricing and market penetration. |
| 2024 |
0.9 million |
$11.7 billion |
Growth driven by expanded indications. |
| 2025 |
1.0 million |
$12.3 billion |
Increased usage, especially in AML indications. |
| 2026 |
1.1 million |
$13.3 billion |
Continued uptake with combination therapies. |
| 2027 |
1.2 million |
$13.8 billion |
Market maturity, steady state. |
| 2028 |
1.3 million |
$13.8 billion |
Approaching patent expiration impact. |
| 2029 |
1.4 million |
$12.5 billion |
Biosimilars entering, price pressure intensifies. |
| 2030 |
1.5 million |
$12 billion |
Biosimilars or generics further erode revenue. |
Key Market Drivers and Risks
-
Drivers:
- Increasing prevalence of hematologic cancers.
- Favorable clinical trial outcomes.
- Growing acceptance of combination regimens.
-
Risks:
- Patent challenges or invalidation.
- Market entry of generics/biosimilars.
- Changes in payer policies reducing reimbursement.
Summary
Venclexta (NDC 60505-0258) remains a high-priced therapy with stable revenues expected through the next few years. Price declines are projected to begin post-2028, aligned with biosimilar entry. Market growth is driven by expanded indications and combination therapies; competition remains moderate until biosimilars are introduced.
Key Takeaways
- Current list price: approximately $13,000/month.
- No immediate biosimilar threat; price stability expected until 2028.
- Revenue growth driven by increased adoption and indications.
- Post-2028, biosimilar market entry expected to reduce prices significantly.
- Market remains highly profitable for brand-name manufacturers through 2027.
FAQs
1. When will biosimilars for venetoclax likely enter the market?
Biosimilars are expected post-2030, following patent expiration and regulatory approval processes.
2. How does combination therapy impact price projections?
Combination regimens tend to command higher prices, increasing overall revenue but possibly influencing discounting strategies.
3. What factors could accelerate price declines?
Patent challenges, biosimilar approvals, and payer pressure for cost containment.
4. Are there regional pricing differences?
Yes. U.S. prices are typically higher than in Europe or other markets due to regulatory and reimbursement variations.
5. How might new indications or clinical data affect the market?
Positive clinical data or new indications can expand utilization, increasing demand and revenue, potentially maintaining higher prices longer.
References
[1] MarketWatch, Global Hematologic Malignancies Market Size & Trends, 2022-2027.
[2] Vanderbilt University Medical Center, Venclexta (venetoclax) pricing data, 2023.
